EUDA Signs Letter of Intent to Potentially Acquire GO POSB

Core Insights - EUDA Health Holdings Limited has signed a Letter of Intent to potentially acquire GO POSB Organoids Pte Ltd, a biotechnology company in Singapore [1][2] - GO POSB has developed a proprietary induced pluripotent stem cell (iPSC) platform that can reprogram human blood cells into clinical-grade stem cells, which have applications in drug discovery, disease modeling, and regenerative medicine [2][3] - The collaboration aims to establish a state-of-the-art iPSC laboratory and cultivation facility in Shenzhen, China, to supply iPSC solutions to hospitals and research centers [3][4] Company Overview - EUDA Health Holdings Limited is a leading non-invasive healthcare provider in Asia, focusing on Singapore, Malaysia, and China, with a mission to address the healthcare needs of over 1.8 billion people in the region [5] - The company aims to lead the transformation of healthcare from reactive treatment to proactive, longevity-focused care, particularly in the fast-growing longevity sector [5] Strategic Initiatives - The collaboration with GO POSB will enable EUDA to supply B2B iPSC solutions to the healthcare ecosystem, including hospitals and biotech developers [4] - Future opportunities include off-the-shelf iPSC-derived products tailored for Asia's wellness and aesthetics markets, complementing EUDA's existing portfolio of stem cell treatments [4]